BIOPHARMA
ByWill Merck’s $9.2 Billion Acquisition of Cidara Therapeutics Reshape the Future of Long-Acting Influenza Prevention?
Rahway, NJ & San Diego, CA | January 2026 Merck & Co., Inc. has confirmed that its approximately…
Can Insilico Medicine’s Hong Kong IPO Signal a Turning Point for AI-Driven Drug Discovery in Global Capital Markets?
Hong Kong | January 4, 2026 Insilico Medicine, a China-based, AI-driven drug discovery company backed by Qiming Venture…
Did NVIDIA Become the Central AI Catalyst for Biopharma in 2025—And Which Players Benefited Most?
2025 marked a pivotal year for artificial intelligence in biopharma. As life sciences companies moved beyond isolated AI…
Which AI Biopharma Startups Truly Won in 2025—And How Did NVIDIA, Big Pharma Collaborations, and Deal Value Define Success?
Executive Perspective 2025 marked a decisive shift for AI biopharma startups—from experimental promise to measurable strategic impact. Success…
AstraZeneca Reports 2025 Performance with Strong Brand Momentum Across Core Therapeutic Areas
AstraZeneca today announced its full-year 2025 results, reflecting continued growth across oncology, cardiovascular-renal-metabolism (CVRM), respiratory & immunology, and…
GSK Reports Full-Year 2025 Results with Strategic Portfolio Focus
GSK today reported its full-year performance for 2025 and outlined its strategic approach to long-term growth across vaccines,…
